Editing Abbott Laboratories (section)

=== Further developments ===
On 16 May 2014, it was announced that Abbott would acquire the [[holding company]] Kalo Pharma Internacional S.L. for $2.9 billion in order to secure the 73% it held of Chilean pharmaceutical company, [[CFR Pharmaceuticals]], which the company said would more than double its branded generic drug portfolio.<ref name=":0" /><ref>{{cite web|url=https://www.bloomberg.com/news/2014-05-16/abbott-agrees-to-purchase-chile-s-cfr-pharmaceuticals.html|title=Abbott to acquire CFR Pharmaceuticals|author=Bloomberg Release|website=[[Bloomberg News]]|date=16 May 2014|access-date=16 May 2014|archive-date=19 December 2014|archive-url=https://web.archive.org/web/20141219070557/http://www.bloomberg.com/news/2014-05-16/abbott-agrees-to-purchase-chile-s-cfr-pharmaceuticals.html|url-status=live}}</ref><ref>{{Cite news|title=Abbott Grows Branded Generics with $3.3B CFR Acquisition|last=Staff|date=15 June 2014|work=[[Gen. Eng. Biotechnol. News|Genetic Engineering & Biotechnology News]]|issue=12|department=News {{!}} Industry Watch|volume=34|page=8|type=Paper}}</ref>

In December 2014, the company acquired Russian pharmaceutical manufacturer Veropharm ([[Voronezh]]) in a deal worth $410 million, which included three manufacturing facilities.<ref name=":0" /><ref>{{cite web|url=https://www.forbes.com/sites/greatspeculations/2014/06/24/abbott-acquires-veropharm-to-expand-presence-in-russia/|title=Abbott Acquires Veropharm To Expand Presence in Russia|website=Forbes|access-date=17 October 2019|archive-date=20 August 2020|archive-url=https://web.archive.org/web/20200820173042/https://www.forbes.com/sites/greatspeculations/2014/06/24/abbott-acquires-veropharm-to-expand-presence-in-russia/|url-status=live}}</ref> Abbott, which already employed 1,400 people in Russia, said it planned to set up a manufacturing presence in the country when the deal closed.<ref>{{cite web|url=https://www.reuters.com/finance/stocks/ABT/key-developments|archive-url=https://web.archive.org/web/20110825120828/http://www.reuters.com/finance/stocks/ABT/key-developments|url-status=dead|archive-date=2011-08-25|title=Abbott Laboratories (ABT) Key Developments |work=Reuters.com}}</ref>

In September 2015, the company announced it had completed its acquisition of Tendyne Holdings, Inc., a private medical device company focused on developing minimally invasive mitral valve replacement therapies.<ref name=autogenerated1>{{Cite web|url=https://abbott.mediaroom.com/2015-09-02-Abbott-Completes-Acquisition-of-Tendyne-Holdings-Inc|title=Abbott Completes Acquisition of Tendyne Holdings, Inc. – Sep 2, 2015|website=Abbott MediaRoom|language=en-us|access-date=2020-02-02|archive-date=21 July 2023|archive-url=https://web.archive.org/web/20230721231449/https://abbott.mediaroom.com/2015-09-02-Abbott-Completes-Acquisition-of-Tendyne-Holdings-Inc|url-status=live}}</ref> Tendyne was acquired for a total transaction value of $250 million.<ref name=autogenerated1 /> In January 2020, the Tendyne Mitral Valve became the world's first commercially available solution for Mitral Valve Replacement Technology.{{citation needed|date=June 2020}} Abbott obtained CE Mark for the device which now makes it possible to implant it in Europe outside of a clinical setting. The US clinical study for federal approval is still ongoing.<ref>{{Cite web|url=https://abbott.mediaroom.com/2020-01-30-Abbotts-Tendyne-TM-Device-Receives-Worlds-First-CE-Mark-for-Transcatheter-Mitral-Valve-Implantation|title=Abbott's Tendyne Device Receives World's First CE Mark for Transcatheter Mitral Valve Implantation – Jan 30, 2020|website=Abbott MediaRoom|language=en-us|access-date=2020-02-02|archive-date=14 August 2023|archive-url=https://web.archive.org/web/20230814195332/https://abbott.mediaroom.com/2020-01-30-Abbotts-Tendyne-TM-Device-Receives-Worlds-First-CE-Mark-for-Transcatheter-Mitral-Valve-Implantation|url-status=live}}</ref>

In February 2016, the company announced it would acquire [[Alere]] for $5.8 billion.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/abbott-to-acquire-alere-for-5-8b/81252306/|title=Abbott to Acquire Alere for $5.8B|work=GEN|date=February 2016|access-date=1 February 2016|archive-date=2 February 2016|archive-url=https://web.archive.org/web/20160202113917/http://www.genengnews.com/gen-news-highlights/abbott-to-acquire-alere-for-5-8b/81252306/|url-status=live}}</ref><ref>{{cite web|url=https://www.bloomberg.com/news/articles/2016-02-01/abbott-to-buy-medical-diagnostics-maker-alere-for-56-a-share|title=Abbott's $5.8 Billion Deal for Alere Is Device Sector's Latest|author=Michelle Cortez|date=1 February 2016|publisher=Bloomberg L.P.|access-date=5 March 2017|archive-date=11 October 2016|archive-url=https://web.archive.org/web/20161011185155/http://www.bloomberg.com/news/articles/2016-02-01/abbott-to-buy-medical-diagnostics-maker-alere-for-56-a-share|url-status=live}}</ref> In January 2017, Abbott announced it would acquire [[St. Jude Medical]] for $25 billion (each share receiving $46.75 in cash & 0.8708 shares of Abbott common stock, equating to an approximate value of $85).<ref name=":0" /><ref>{{cite web|url=https://www.bloomberg.com/news/articles/2016-04-28/abbott-agrees-to-buy-st-jude-medical-for-25-billion|title=Abbott to Buy St. Jude Medical in Deal Valued at About $25 Billion|author=Michelle Cortez|date=28 April 2016|publisher=Bloomberg L.P.|access-date=5 March 2017|archive-date=7 March 2020|archive-url=https://web.archive.org/web/20200307111910/https://www.bloomberg.com/news/articles/2016-04-28/abbott-agrees-to-buy-st-jude-medical-for-25-billion|url-status=live}}</ref><ref>{{cite web|url=https://www.bloomberg.com/news/videos/2016-04-28/abbott-st-jude-combination-why-it-makes-sense|title=Abbott-St. Jude Combination: Why It Makes Sense|date=28 April 2016|publisher=Bloomberg L.P.|access-date=5 March 2017|archive-date=15 April 2017|archive-url=https://web.archive.org/web/20170415200817/https://www.bloomberg.com/news/videos/2016-04-28/abbott-st-jude-combination-why-it-makes-sense|url-status=live}}</ref> On 3 October 2017, the company closed the Alere acquisition making the surviving entity the market leader player in the $7 billion point-of-care diagnostic space within the broader $50 billion in-vitro diagnostics market with this takeover.<ref>{{cite web|url=http://www.nasdaq.com/article/abbott-to-gain-from-aleres-takeover-due-for-oct-3-closure-cm854254|title=Abbott to Gain from Alere's Takeover Due for Oct 3 Closure|work=GEN|access-date=5 October 2017|archive-date=5 October 2017|archive-url=https://web.archive.org/web/20171005141211/http://www.nasdaq.com/article/abbott-to-gain-from-aleres-takeover-due-for-oct-3-closure-cm854254|url-status=live}}</ref> With the acquisition of Alere, the company also obtained the subsidiary Arriva Medical, which is the largest mail-order diabetic supplier.{{citation needed|date=June 2020}} Arriva Medical announced business closure after Abbott acquisition effective 31 December 2017.<ref>{{cite web|url=http://www.hmenews.com/article/embattled-arriva-medical-closes|title=Embattled Arriva Medical closes|work=GEN|access-date=6 December 2017|archive-date=6 December 2017|archive-url=https://web.archive.org/web/20171206221738/http://www.hmenews.com/article/embattled-arriva-medical-closes|url-status=live}}</ref>

In 2017, the FDA approved Abbott's FreeStyle Libre glucose monitoring system, which reads glucose levels through a self-applied sensor without finger pricks.<ref>{{cite web|url=https://www.medicaldevice-network.com/news/newsfda-approves-abbotts-freestyle-libre-glucose-monitoring-system-5938126/|title=FDA approves Abbott's Freestyle Libre glucose monitoring system|website=Medical Device Network|date=29 September 2017|access-date=17 October 2019|archive-date=17 October 2019|archive-url=https://web.archive.org/web/20191017194312/https://www.medicaldevice-network.com/news/newsfda-approves-abbotts-freestyle-libre-glucose-monitoring-system-5938126/|url-status=live}}</ref>

In August 2018, Reuters reported that Abbott Laboratories was among the top five companies for branded generic drugs in Russia.<ref>{{cite news |title=Factbox: U.S. companies with exposure to Russia |url=https://www.reuters.com/article/us-usa-russia-sanctions-companies-factbo/factbox-u-s-companies-with-exposure-to-russia-idUSKBN1KU2L8 |work=Reuters |date=9 August 2018 |access-date=29 January 2019 |archive-date=1 December 2020 |archive-url=https://web.archive.org/web/20201201061738/https://www.reuters.com/article/us-usa-russia-sanctions-companies-factbo/factbox-u-s-companies-with-exposure-to-russia-idUSKBN1KU2L8 |url-status=live }}</ref>

[[File:ID Now testing (51038387158).jpg|thumb|Nucleic acid testing for COVID-19 conducted using an Abbott Laboratories ID Now device]]
In November 2018, Abbott received United States FDA clearance for FreeStyle LibreLink, a glucose reader [[smartphone app]].<ref>{{cite web|url=https://www.mobihealthnews.com/content/new-fda-clearance-abbott-freestyle-libre-users-can-ditch-handheld-readers-app|title=With new FDA clearance, Abbott Freestyle Libre users can ditch handheld readers for an app|website=Mobi Health News|date=November 2018|access-date=17 October 2019|archive-date=20 February 2020|archive-url=https://web.archive.org/web/20200220045000/https://www.mobihealthnews.com/content/new-fda-clearance-abbott-freestyle-libre-users-can-ditch-handheld-readers-app|url-status=live}}</ref>

In January 2019 purchased Cephea Valve Technologies, Inc. which is developing a less-invasive replacement heart valve for people with mitral valve disease.<ref>{{cite web|url=https://www.biospace.com/article/abbott-to-acquire-cephea-valve-technologies-inc-/|title=Abbott To Acquire Cephea Valve Technologies, Inc.|website=BioSpace|access-date=2 June 2019|archive-date=20 August 2020|archive-url=https://web.archive.org/web/20200820173325/https://www.biospace.com/article/abbott-to-acquire-cephea-valve-technologies-inc-/|url-status=live}}</ref>

In March 2020, Abbott received [[emergency use authorization]] (EUA) from the US FDA for a [[SARS-CoV-2]] test during the [[COVID-19 pandemic]].<ref>{{cite web|url=https://www.ibtimes.com/fda-approves-abbott-laboratories-coronavirus-test-company-ship-150000-kits-2942677 |title=FDA Approves Abbott Laboratories Coronavirus Test, Company To Ship 150,000 Kits |date=19 March 2020 |website=International Business Times |archive-url=https://web.archive.org/web/20200320210743/https://www.ibtimes.com/fda-approves-abbott-laboratories-coronavirus-test-company-ship-150000-kits-2942677 |archive-date=20 March 2020 |url-status=live}}</ref> The tester is small (comparable to a small toaster), and produces results within 13 minutes.<ref>{{Cite web|url=https://www.usatoday.com/story/news/health/2020/03/28/coronavirus-fda-authorizes-abbott-labs-fast-portable-covid-test/2932766001/|title='A game changer': FDA authorizes Abbott Labs' portable, 5-minute coronavirus test the size of a toaster|last=Hauck|first=Grace|website=USA Today|language=en-US|access-date=2020-03-30|archive-date=28 April 2020|archive-url=https://web.archive.org/web/20200428170404/https://www.usatoday.com/story/news/health/2020/03/28/coronavirus-fda-authorizes-abbott-labs-fast-portable-covid-test/2932766001/|url-status=live}}</ref> Detroit received these tests on April 1, 2020.<ref>{{Cite news |url=https://www.washingtonpost.com/health/2020/04/01/scramble-rapid-coronavirus-tests-everybody-wants/ |title=The scramble for the rapid coronavirus tests everybody wants |last=Mufson |first=Steven |newspaper=The Washington Post |language=en |access-date=2020-04-02 |archive-date=10 February 2021 |archive-url=https://web.archive.org/web/20210210022633/https://www.washingtonpost.com/health/2020/04/01/scramble-rapid-coronavirus-tests-everybody-wants/ |url-status=live }}</ref><ref>{{Cite web |url=https://techcrunch.com/2020/04/01/detroit-to-be-first-to-deploy-abbott-labs-5-minute-covid-19-test-mayor-says/ |title=Detroit to be first to deploy Abbott Labs' 5-minute COVID-19 test, mayor says |last=Burns |first=Matt |website=TechCrunch |date=2 April 2020 |language=en-US |access-date=2020-04-02 |archive-date=17 July 2024 |archive-url=https://web.archive.org/web/20240717135224/https://techcrunch.com/2020/04/01/detroit-to-be-first-to-deploy-abbott-labs-5-minute-covid-19-test-mayor-says/ |url-status=live }}</ref> Also in March, the firm received EUA for a molecular COVID-19 test that runs on its m2000 RealTime lab-based platform.<ref>{{cite web|title=Abbott receives FDA emergency use authorization for coronavirus test|last=Newmaker|first=Chris|url=https://www.massdevice.com/abbott-receives-fda-emergency-use-authorization-for-coronavirus-test/|website=massdevice.com|access-date=13 April 2021|date=19 March 2020|archive-date=13 April 2021|archive-url=https://web.archive.org/web/20210413192459/https://www.massdevice.com/abbott-receives-fda-emergency-use-authorization-for-coronavirus-test/|url-status=live}}</ref> In April 2020, itt received EUA from the FDA for its third COVID-19 test, an antibody test that helps detect the IgG antibody to SARS-CoV-2 using the company's ARCHITECT laboratory instruments.<ref name="medtechcorona">{{cite web|title=Abbott enters coronavirus antibody testing fray|last=Rachal|first=Maria|url=https://www.medtechdive.com/news/abbott-enters-coronavirus-antibody-testing-fray/576068/|website=medtechdive.com|date=15 April 2020|access-date=13 April 2021|archive-date=13 April 2021|archive-url=https://web.archive.org/web/20210413192459/https://www.medtechdive.com/news/abbott-enters-coronavirus-antibody-testing-fray/576068/|url-status=live}}</ref> In May 2020, it received EUA from the FDA for another lab-based COVID-19 antibody test that helps detect the IgG antibody to SARS-CoV-2 using the company's Alinity i system.<ref name="medtechcorona" /><ref>{{cite web|title=Latest Abbott coronavirus antibody test receives FDA emergency use OK|last=Slabodkin|first=Greg|url=https://www.medtechdive.com/news/latest-abbott-coronavirus-antibody-test-receives-fda-emergency-use-ok/577667/|website=medtechdive.com|date=11 May 2020|access-date=13 April 2021|archive-date=13 April 2021|archive-url=https://web.archive.org/web/20210413201434/https://www.medtechdive.com/news/latest-abbott-coronavirus-antibody-test-receives-fda-emergency-use-ok/577667/|url-status=live}}</ref> Also in May, it received EUA from the FDA for a molecular COVID-19 test for use on the company's Alinity molecular laboratory instrument.<ref>{{Cite journal |last1=Perchetti |first1=Garrett A. |last2=Pepper |first2=Gregory |last3=Shrestha |first3=Lasata |last4=LaTurner |first4=Katrina |last5=Yae Kim |first5=Da |last6=Huang |first6=Meei-Li |last7=Jerome |first7=Keith R. |last8=Greninger |first8=Alexander L.|author8-link=Alexander L. Greninger |date=July 2021 |title=Performance characteristics of the Abbott Alinity m SARS-CoV-2 assay |journal=Journal of Clinical Virology |volume=140 |pages=104869 |doi=10.1016/j.jcv.2021.104869 |issn=1386-6532 |pmc=8118701 |pmid=34023572}}</ref><ref>{{cite web|title=Two Abbott COVID-19 tests receive EUA|last=Boyle|first=Annette|url=https://www.bioworld.com/articles/435056-two-abbott-covid-19-tests-receive-eua|website=bioworld.com|date=12 May 2020|access-date=13 April 2021|archive-date=13 April 2021|archive-url=https://web.archive.org/web/20210413201443/https://www.bioworld.com/articles/435056-two-abbott-covid-19-tests-receive-eua|url-status=live}}</ref>

In August 2020, Abbott received EUA from the FDA for its credit-card-sized $5, 15-minute, portable COVID-19 antigen test, BinaxNOW, compatible with the NAVICA mobile app.<ref>{{cite web|title=Abbott wins EUA for COVID-19 test that runs off a card|last=Newmarker|first=Chris|url=https://www.massdevice.com/breaking-abbott-wins-eua-for-covid-19-test-that-runs-off-a-card/|website=massdevice.com|date=27 August 2020|access-date=13 April 2021|archive-date=13 April 2021|archive-url=https://web.archive.org/web/20210413201432/https://www.massdevice.com/breaking-abbott-wins-eua-for-covid-19-test-that-runs-off-a-card/|url-status=live}}</ref><ref>{{cite news|title=This $5 rapid test is a potential game-changer in COVID-19 testing|url=https://abc7.com/binaxnow-binax-now-coronavirus-test-rapid/6391998/ |website=abc7.com|date=27 August 2020}}</ref>

In October 2020, Abbott received EUA from the FDA for its lab-based COVID-19 IgM antibody blood test.<ref>{{cite web|title=Abbott wins FDA EUA for COVID-19 IgM antibody test|last=Whooley|first=Sean|url=https://www.massdevice.com/abbott-wins-fda-eua-for-covid-19-igm-antibody-test/|website=massdevice.com|date=13 October 2020|access-date=14 April 2021|archive-date=14 April 2021|archive-url=https://web.archive.org/web/20210414183002/https://www.massdevice.com/abbott-wins-fda-eua-for-covid-19-igm-antibody-test/|url-status=live}}</ref> In December 2020, its rapid (20') antigen BinaxNOW COVID-19 test received EUA from the FDA for home use.<ref>{{Cite journal |last1=Perchetti |first1=Garrett A. |last2=Huang |first2=Meei-Li |last3=Mills |first3=Margaret G. |last4=Jerome |first4=Keith R. |author5-link=Alexander L. Greninger |last5=Greninger |first5=Alexander L. |date=2021-02-18 |editor-last=Loeffelholz |editor-first=Michael J. |title=Analytical Sensitivity of the Abbott BinaxNOW COVID-19 Ag Card |journal=Journal of Clinical Microbiology |language=en |volume=59 |issue=3 |pages=e02880–20 |doi=10.1128/JCM.02880-20 |issn=0095-1137 |pmc=8106729 |pmid=33310764}}</ref><ref>{{cite web|title=Abbott Labs' at-home, $25 rapid COVID-19 test gets EUA from FDA|last=Kilgore|first=Tomi|url=https://www.marketwatch.com/story/abbott-labs-at-home-25-rapid-covid-19-test-gets-eua-from-fda-2020-12-16|website=marketwatch.com|date=16 December 2020|access-date=14 April 2021|archive-date=14 April 2021|archive-url=https://web.archive.org/web/20210414183002/https://www.marketwatch.com/story/abbott-labs-at-home-25-rapid-covid-19-test-gets-eua-from-fda-2020-12-16|url-status=live}}</ref> ''Forbes'' reported in January 2021 that the firm had delivered more than 400 million COVID-19 tests, 300 million in the fourth quarter of 2020.<ref>{{cite web|title=Abbott Profits Rise As Covid-19 Diagnostic Sales Eclipse 400 Million Tests|last=Japsen|first=Bruce|url=https://www.forbes.com/sites/brucejapsen/2021/01/27/abbott-profits-jump-as-covid-19-test-sales-surpass-400-million/?sh=7ad91257124a|website=Forbes|date=27 January 2021|access-date=14 April 2021|archive-date=14 April 2021|archive-url=https://web.archive.org/web/20210414183002/https://www.forbes.com/sites/brucejapsen/2021/01/27/abbott-profits-jump-as-covid-19-test-sales-surpass-400-million/?sh=7ad91257124a|url-status=live}}</ref>

In September 2021, Abbott acquired Walk Vascular, LLC.<ref>{{Cite web|url=https://www.biospace.com/article/releases/abbott-expands-peripheral-vascular-offerings-with-acquisition-of-walk-vascular-llc/?s=79|title=Abbott Expands Peripheral Vascular Offerings with Acquisition of Walk Vascular, LLC|date=2 September 2021 |access-date=3 September 2021|archive-date=3 September 2021|archive-url=https://web.archive.org/web/20210903201150/https://www.biospace.com/article/releases/abbott-expands-peripheral-vascular-offerings-with-acquisition-of-walk-vascular-llc/?s=79|url-status=live}}</ref>

In January 2022, Abbott introduced Lingo, a line of consumer biowearable sensors that collects a range of biological readings to optimize exercise and nutrition regimens.<ref>{{cite news|url=https://www.fiercebiotech.com/medtech/abbott-ceo-ford-unveils-lingo-line-sports-biosensors-based-diabetes-monitoring-tech|author=Andrea Park|date=January 6, 2022|title=Abbott unveils Lingo line of sports biosensors based on diabetes monitoring tech|work=Fierce Biotech|access-date=23 January 2023|archive-date=23 January 2023|archive-url=https://web.archive.org/web/20230123191646/https://www.fiercebiotech.com/medtech/abbott-ceo-ford-unveils-lingo-line-sports-biosensors-based-diabetes-monitoring-tech|url-status=live}}</ref>

Following the 2022 Russian invasion of Ukraine, Abbott Laboratories continued its business operations in Russia while suspending non-essential activities such as new investments and advertising.<ref>{{Cite web |last=Varney |first=Sarah |date=2022-03-10 |title=Which Companies Aren't Exiting Russia? Big Pharma |url=https://kffhealthnews.org/news/article/big-pharma-reaction-russia-ukraine-war/ |access-date=2025-02-20 |website=KFF Health News |language=en-US}}</ref><ref>{{Cite web |title=Фармкомпании сворачивают операции в России в ответ на военную операцию в Украине |url=https://www.business-humanrights.org/ru/%D1%81%D0%B2%D0%B5%D0%B6%D0%B8%D0%B5-%D0%BD%D0%BE%D0%B2%D0%BE%D1%81%D1%82%D0%B8/%D1%84%D0%B0%D1%80%D0%BC%D0%BA%D0%BE%D0%BC%D0%BF%D0%B0%D0%BD%D0%B8%D0%B8-%D1%81%D0%B2%D0%BE%D1%80%D0%B0%D1%87%D0%B8%D0%B2%D0%B0%D1%8E%D1%82-%D0%BE%D0%BF%D0%B5%D1%80%D0%B0%D1%86%D0%B8%D0%B8-%D0%B2-%D1%80%D0%BE%D1%81%D1%81%D0%B8%D0%B8-%D0%B2-%D0%BE%D1%82%D0%B2%D0%B5%D1%82-%D0%BD%D0%B0-%D0%B2%D0%BE%D0%B5%D0%BD%D0%BD%D1%83%D1%8E-%D0%BE%D0%BF%D0%B5%D1%80%D0%B0%D1%86%D0%B8%D1%8E-%D0%B2-%D1%83%D0%BA%D1%80%D0%B0%D0%B8%D0%BD%D0%B5/ |access-date=2025-02-20 |website=Business & Human Rights Resource Centre |language=ru}}</ref> Research from [[Yale School of Management]] evaluating corporate responses to the invasion placed Abbott in the "Buying Time" category with a "Grade D" rating, indicating that it postponed future investments and marketing while continuing substantive business in Russia.<ref>{{Cite web |title=Over 1,000 Companies Have Curtailed Operations in Russia—But Some Remain {{!}} Yale School of Management |url=https://som.yale.edu/story/2022/over-1000-companies-have-curtailed-operations-russia-some-remain |access-date=2025-02-20 |website=som.yale.edu |language=en}}</ref>

In May 2022, Abbott received 510(k) clearance from the FDA for FreeStyle Libre 3, the latest version of its continuous glucose monitor.<ref>{{cite news|url=https://www.medtechdive.com/news/abbott-libre-3-CGM-fda-clearance/624591/|author=Nick Paul Taylor|date=May 31, 2022|title=Abbott's Libre 3 glucose monitor gets FDA clearance as CGM market intensifies|work=MedTechDive|access-date=29 December 2022|archive-date=29 December 2022|archive-url=https://web.archive.org/web/20221229030224/https://www.medtechdive.com/news/abbott-libre-3-CGM-fda-clearance/624591/|url-status=live}}</ref>

In August 2022, Abbott received FDA approval for Proclaim Plus, a multi-use spinal cord stimulation system designed to target chronic pain. The Proclaim Plus system is capable of treating six independent pain sites and has a recharge-free battery life of up to 10 years.<ref>{{cite news|url=https://www.fiercebiotech.com/medtech/abbott-proclaims-fda-approval-neurostimulator-treat-pain-six-areas-once#:~:text=Abbott%20proclaims%20FDA%20approval%20of,in%206%20areas%20at%20once&text=A%20spinal%20cord%20stimulation%20device,of%20the%20body%20at%20once|author=Andrea Park|date=August 23, 2022|title=Abbott proclaims FDA approval of neurostimulator to treat pain in 6 areas at once|work=Fierce Biotech|access-date=23 January 2023|archive-date=23 January 2023|archive-url=https://web.archive.org/web/20230123190313/https://www.fiercebiotech.com/medtech/abbott-proclaims-fda-approval-neurostimulator-treat-pain-six-areas-once#:~:text=Abbott%20proclaims%20FDA%20approval%20of,in%206%20areas%20at%20once&text=A%20spinal%20cord%20stimulation%20device,of%20the%20body%20at%20once|url-status=live}}</ref>

In October 2022, Abbott received EUA from the FDA for its real-time [[Polymerase chain reaction|PCR]] test Alinity m MPXV; this marks the first FDA emergency authorization for commercial monkeypox testing.<ref>{{cite news|url=https://www.medtechdive.com/news/abbott-eua-fda-monkeypox-test/633667/|author=Nick Paul Taylor|date=October 10, 2022|title=Abbott lands FDA emergency authorization for first commercial monkeypox test|work=MedTechDive|access-date=29 December 2022|archive-date=29 December 2022|archive-url=https://web.archive.org/web/20221229024014/https://www.medtechdive.com/news/abbott-eua-fda-monkeypox-test/633667/|url-status=live}}</ref>

On July 5, 2023, Abbott received approval from the FDA for its leadless pacemaker system Aveir DR.<ref name="aveirdr" /> In August, the company announced it would acquire Bigfoot Biomedical.<ref>{{cite web | url=https://www.biospace.com/article/releases/abbott-to-acquire-bigfoot-biomedical-furthering-efforts-to-develop-personalized-connected-solutions-for-people-with-diabetes/?s=79 | title=Abbott to Acquire Bigfoot Biomedical, Furthering Efforts to Develop Personalized, Connected Solutions for People with Diabetes | date=5 September 2023 | access-date=7 September 2023 | archive-date=7 September 2023 | archive-url=https://web.archive.org/web/20230907113323/https://www.biospace.com/article/releases/abbott-to-acquire-bigfoot-biomedical-furthering-efforts-to-develop-personalized-connected-solutions-for-people-with-diabetes/?s=79 | url-status=live }}</ref>

Today, Abbott operates in over 160 countries and sources from at least 62 suppliers worldwide.<ref>{{citation|author=Baker Batte|title=Study finds quick way of testing for hepatitis B|date=27 June 2019|url=https://observer.ug/lifestyle/61182-study-finds-quick-way-of-testing-for-hepatitis-b|access-date=3 April 2020|archive-date=5 October 2022|archive-url=https://web.archive.org/web/20221005032245/https://observer.ug/lifestyle/61182-study-finds-quick-way-of-testing-for-hepatitis-b|url-status=live}}</ref><ref>{{cite web | url=https://www.coreties.com/consignees/abbott-laboratories-int-l-llc | title=Abbott Laboratories Importer Profile: Shipment Insights and Market Trends | access-date=21 July 2024 | archive-date=21 July 2024 | archive-url=https://web.archive.org/web/20240721002138/https://www.coreties.com/consignees/abbott-laboratories-int-l-llc | url-status=live }}</ref>